Absolute Benefit of Adjuvant Endocrine Therapies for Premenopausal Women With Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Early Breast Cancer: TEXT and SOFT Trials

PURPOSE: Risk of recurrence is the primary consideration in breast cancer adjuvant therapy recommendations. The TEXT (Tamoxifen and Exemestane Trial) and SOFT (Suppression of Ovarian Function Trial) trials investigated adjuvant endocrine therapies for premenopausal women with hormone receptor–positi...

全面介紹

Na minha lista:
書目詳細資料
發表在:J Clin Oncol
Main Authors: Regan, Meredith M., Francis, Prudence A., Pagani, Olivia, Fleming, Gini F., Walley, Barbara A., Viale, Giuseppe, Colleoni, Marco, Láng, István, Gómez, Henry L., Tondini, Carlo, Pinotti, Graziella, Price, Karen N., Coates, Alan S., Goldhirsch, Aron, Gelber, Richard D.
格式: Artigo
語言:Inglês
出版: American Society of Clinical Oncology 2016
主題:
ORIGINAL REPORTS
在線閱讀:https://ncbi.nlm.nih.gov/pmc/articles/PMC4962708/
https://ncbi.nlm.nih.gov/pubmed/27044936
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2015.64.3171
標簽: 添加標簽
沒有標簽, 成為第一個標記此記錄!

相似書籍